The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I/II trial of autophagy inhibition in combination with neoadjuvant gemcitabine in patients with high-risk pancreatic adenocarcinoma: Safety, clinical response, and correlative studies.
Michael T. Lotze
No relevant relationships to disclose
Brian A. Boone
No relevant relationships to disclose
Amer H. Zureikat
No relevant relationships to disclose
Nathan Bahary
No relevant relationships to disclose
David Lehman
No relevant relationships to disclose
Lance A. Liotta
No relevant relationships to disclose
Herbert J. Zeh
No relevant relationships to disclose